Cann Group Ltd. · ASX:CAN
Cann — H1 2023 Earnings Presentation
20 slides from Cann's earnings presentation, Feb 28, 2023
Slide 1: ASX Announcement: Investor presentation
ASX ANNOUNCEMENT 28 February 2023 Investor presentation For personal use only 28 February 2023 – As announced on 24 February 2023, Cann Group Limited (ASX: CAN) (Cann or the Company) will be presenting an investor update webinar and Q&A with Chairman, Allan McCallum, CEO, Peter Koetsier and CFO, Deb
Slide 2: 2023 Half Year results and business update
For personal use only Cann Group Limited 2023 Half Year results and business update February 2023 Cann Group Limited ABN 25 603 949 739
Slide 3: Disclaimer | Important notice
Disclaimer | Important notice This presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 949 739) (Cann). For personal use only Summary information This Presentation contains summary information about Cann and its activities which is current as at the date of this Presentat
Slide 4: Agenda
Agenda For personal use only Introduction and strategic priorities 1 Half year financials 2 S3 clinical trial & Satipharm platform 3 Efficiencies of scale at Mildura facility 4 Outlook commentary 5 Q&A 6
Slide 5: Introducing new CEO
For personal use only Introducing new CEO Allan McCallum Non-Executive Chairman
Slide 6: Introducing new CEO, Peter Koetsier
Introducing new CEO, Peter Koetsier For personal use only • Commenced January 16, 2023 • 30 years of experience in biopharmaceutical commercial leadership roles, including General Management and Global Marketing • Previous role as Head of Asia Pacific & ANZ for French biopharmaceutical company, Ipse
Slide 7: Early impressions
For personal use only Early impressions Peter Koetsier Chief Executive Officer
Slide 8: Early impressions
Early impressions For personal use only • Cann Group has done the ‘heavy lifting’ in terms of establishing a world-class production facility; building expertise and capability from genetics to finished product; and developing a B-to-B business model that can take full advantage of our scale and tech
Slide 9: Financials
For personal use only Financials Deborah Ambrosini Chief Financial Officer
Slide 10: Financials
Financials CANN GROUP LIMITED HALF YEAR RESULTS For personal use only 31-Dec-22 31-Dec-21 Movement Movement • Half year revenues up 83% on the same period in prior year 000's 000's $ % Revenue • Admin and corporate costs* increase in line with expectations as Revenue from customers 5,819 3,172 2,647
Slide 11: S3 Clinical Trial update & Satipharm platform
For personal use only S3 Clinical Trial update & Satipharm platform
Slide 12: S3 Clinical Trial update
S3 Clinical Trial update For personal use only • A preliminary review of the analysis of the primary end- points has not shown a statistically superior response compared to placebo • While study participants receiving Satipharm CBD showed a positive response, that response was not statistically supe
Slide 13: Satipharm platform
Satipharm platform A unique technology platform that supports product development across For personal use only multiple market segments • Developing registerable, differentiated & IP protected medicinal cannabis products for global distribution • Patented formulation resulting in better stability an
Slide 14: Efficiencies of scale at Mildura facility
For personal use only Efficiencies of scale at Mildura facility
Slide 15: Efficiencies of scale at Mildura Facility
Efficiencies of scale at Mildura Facility First finished dried flower products cultivated and manufactured in Mildura were released For personal use only to the market during the December quarter. Focus on flower quality and volume Cultivation Operations Largest single Glasshouse micro- harvest in w
Slide 16: Outlook commentary
For personal use only Outlook commentary
Slide 17: Outlook commentary
Outlook commentary For personal use only Immediate focus on December revenues Mildura quickly streamlining Opportunity to reflect significant transitioning to scale- operations; securing substantially increase upturn in sales trend based efficiencies – efficiencies and market share in a which is exp
Slide 18: Near-term priorities
Near-term priorities For personal use only • Optimise production systems at Mildura so that scale efficiencies can be realised • Work with current and prospective customers to ensure Cann is ready to supply quality product in volumes required • Continue to streamline operations to minimise overhead
Slide 19: Q&A
For personal use only Q&A
Slide 20: Contact
For personal use only Contact Peter Koetsier Chief Executive Officer peter.koetsier@canngrouplimited.com Deborah Ambrosini Chief Financial Officer deborah.ambrosini@canngrouplimited.com canngrouplimited.com | +61 3 9095 7188